These findings reinforce the observations made by Chen J. et al. (2020) and Tang Y. et al. (2021) [33,37], suggesting that the combined assessment of PD-L1 and CD8+ TILs may guide selection for immunotherapeutic strategies in cervical cancer, especially those with advanced clinical stage. This evidence concerns the gene CD8A and cervical carcinoma.